文献速递浆细胞疾病

循环肿瘤细胞在初诊多发性骨髓瘤IMS-IMWG 2025分期中识别播散性基因组高危表型

Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.
PubMed 文献 · Leukemia · 2026-09-07

该研究回顾性分析NICHE队列631例多发性骨髓瘤患者,评估循环肿瘤细胞(CTC)能否优化2025 IMS-IMWG共识基因组分期(CGS)。在410例初诊患者中CTC可检出率为63.9%,0.38%的CTC阈值独立预测更差的无进展生存期(PFS),并在CGS高危亚组中进一步分层,定义出占可评估初诊患者12.4%的播散性基因组高危表型。

要点

  • 初诊MM患者CTC可检出率63.9%,与骨髓浆细胞浸润及高危细胞遗传学异常累积相关。
  • CTC阈值0.38%独立预测更差PFS,并在CGS高危亚组中精化预后分层。
  • CGS高危/CTC高患者PFS最短,构成播散性基因组高危表型(占可评估初诊患者12.4%)。

核心结论

  • CTC整合CGS支持微创基线风险分层和纵向疾病监测。
  • CTC可在CGS高危亚组内进一步识别PFS更短的播散性基因组高危表型。

研究设计与样本

  • 回顾性分析NICHE队列(NCT04645199)631例多发性骨髓瘤患者,跨疾病阶段进行CTC评估。
  • 410例初诊时评估CTC,359例初诊患者有充分随访用于生存分析。

主要发现

  • 410例初诊患者中CTC可检出率为63.9%,与骨髓浆细胞浸润和高危细胞遗传学异常累积相关。
  • 359例初诊患者中,队列衍生CTC阈值0.38%在多变量调整后独立预测更差PFS。
  • CTC在CGS高危亚组内精化预后分层,CGS高危/CTC高患者PFS最短。
  • 播散性基因组高危表型占可评估初诊患者的12.4%(39/314)。
  • 127例非进展状态随访中可检出CTC与更差结局相关;120例配对检测中CTC联合骨髓MRD可分层结局。

关键数值与推荐

  • CTC阈值0.38%用于定义CTC-high并独立预测更差PFS(多变量调整后)。
  • CGS高危/CTC高定义为播散性基因组高危表型,占可评估NDMM的12.4%(39/314)。

临床怎么用

  • 初诊MM可检测CTC以在CGS基础上进一步识别高危患者。
  • CTC可联合骨髓MRD用于纵向疾病监测和结局分层。

局限性

  • 回顾性队列研究设计。
  • CTC阈值0.38%为队列衍生,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2025 IMS-IMWG consensus genomic staging (CGS) system has improved genomic risk stratification in newly diagnosed multiple myeloma (NDMM), yet does not capture whether high-risk clones have acquired a disseminated phenotype. We investigated whether circulating tumor cells (CTC) refine CGS and enable longitudinal residual disease monitoring. We retrospectively analyzed 631 MM patients from the NICHE cohort (NCT04645199) who underwent CTC assessment across disease phases. Among 410 patients assessed at diagnosis, CTC were detectable in 63.9% and correlated with both bone marrow plasma cell infiltration and accumulation of high-risk cytogenetic abnormalities. In 359 NDMM patients with adequate follow-up, a cohort-derived CTC threshold of 0.38% independently predicted inferior progression-free survival (PFS) after multivariable adjustment. Importantly, CTC refined prognostic stratification specifically within the CGS high-risk subgroup. Patients with CGS high-risk/CTC-high disease had the shortest PFS, thereby defining a disseminated genomic high-risk phenotype comprising 12.4% (39/314) of evaluable NDMM patients. In follow-up cohorts, detectable CTC were associated with inferior outcomes in 127 patients assessed during non-progressive disease states, whereas combined CTC and bone marrow minimal residual disease assessment stratified outcomes in 120 patients with paired measurements. Overall, CTC-integrated CGS supports minimally invasive baseline risk stratification and longitudinal disease monitoring.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Li Y, Shi L, Yan W, et al. Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma. Leukemia. 2026. PMID: 42706314. doi:10.1038/s41375-026-03133-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。